ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-08 Significant Split/Dividend

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 2026-08-14			5-day change	1st Jan Change
676.00 ^KRW	-2.03%		0.00%	-78.40%

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
25-04-04	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE

Market Cap	60.91B 43.93M 37.7M 35.39M 32.32M 61M 4.19B 61.29M 419M 162M 2.11B 165M 161M 7B	P/E 2024	-4.02x	P/E 2025	-7.21x
Enterprise Value	32.57B 23.49M 20.16M 18.93M 17.29M 32.62M 2.24B 32.78M 224M 86.8M 1.13B 88.21M 86.3M 3.74B	EV / Sales 2024	282x	EV / Sales 2025	288x
Free-Float	67.24%	Yield 2024 *	-	Yield 2025	-

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
25-04-04	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE
24-12-29	Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd..	CI
24-12-25	KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc.	CI
24-12-22	Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion.	CI
24-12-22	ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
24-12-17	KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc.	CI
24-12-04	ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc..	CI
24-12-04	ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
24-11-10	ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
24-11-10	ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion.	CI
24-10-27	ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
23-12-27	Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	CI

1 day	-2.03%
Current month	+1.96%
1 month	-16.02%
3 months	-68.34%
6 months	-80.57%
Current year	-78.40%

Abion Inc. Stock

Stocks

A203400

KR7203400007

Biotechnology & Medical Research

Valuation: Abion Inc.

Chart: Abion Inc.

Latest news : Abion Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Abion Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

1 month	587	1,093
Current year	570	4,335
1 year	570	4,510
3 years	570	7,277.78
5 years	570	14,694.44
10 years	570	14,694.44

Manager	Title	Age	Since
Young-Gi Shin CEO	Chief Executive Officer	55	2010-07-31
Seong-Yun Woo DFI	Director of Finance/CFO	45	2025-03-27
Gi-Ryong Jang COO	Chief Operating Officer	46	2025-12-31

Director	Title	Age	Since
Young-Gi Shin BRD	Director/Board Member	55	2014-12-30
Jin-Wook Yang BRD	Director/Board Member	56	2022-03-24
Geun-Chul Park BRD	Director/Board Member	70	-

Date	Insider	Type	Quantity	% Market Cap.
12/8/25	Sun-mi Chang	Free	27	0.0001%
12/8/25	Yang-mi Lim	Buy	115	0.0002%
12/8/25	Yang-mi Lim	Free	92	0.0002%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABION INC.	-2.03%	0.00%	-80.66%	-86.33%	43.99M
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	71.35B
ARGENX SE	+2.09%	+2.28%	+49.95%	+91.14%	64.17B
BIONTECH SE	-1.58%	-1.02%	+6.85%	-7.22%	28.65B
INSMED INCORPORATED	+0.19%	-5.03%	-6.11%	+473.96%	27.06B
WUXI BIOLOGICS (CAYMAN) INC.	-2.78%	+4.47%	+52.49%	+14.43%	27.33B
GENMAB A/S	-1.68%	+0.33%	+36.86%	-17.91%	20.47B
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	19.36B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.57%	-4.06%	+10.79%	+515.61%	15.96B
EXELIXIS, INC.	-0.01%	+4.23%	+47.86%	+155.59%	14.05B
Average	-0.18%	+2.05%	+44.85%	+166.33%	28.84B
Weighted average by Cap.	+0.82%	+3.31%	+54.90%	+154.06%

	2024	2025
Net sales	760M 548K 470K 441K 403K 761K 52.26M 764K 5.22M 2.02M 26.36M 2.06M 2.01M 87.32M	880M 635K 545K 511K 467K 881K 60.54M 886K 6.05M 2.35M 30.54M 2.38M 2.33M 101M
Net income	-43.38B -31.29M -26.85M -25.21M -23.02M -43.45M -2.98B -43.66M -298M -116M -1.51B -117M -115M -4.99B	-29.06B -20.96M -17.99M -16.89M -15.42M -29.11M -2B -29.25M -200M -77.45M -1.01B -78.7M -77M -3.34B
Net Debt	14.05B 10.13M 8.7M 8.16M 7.45M 14.07M 966M 14.14M 96.58M 37.43M 487M 38.04M 37.21M 1.61B	-28.33B -20.44M -17.54M -16.46M -15.04M -28.38M -1.95B -28.51M -195M -75.5M -983M -76.73M -75.06M -3.26B